HRTX
$16.31
Heron Therapeutics
$.27
1.68%
HRTX
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.65)
Revenue:  $16.98 Mil
Tuesday
Nov 10
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when HRTX reports earnings?
Beat
Meet
Miss

Where is HRTX's stock price going from here?
Up
Flat
Down
Stock chart of HRTX
Analysts
Summary of analysts' recommendations for HRTX
Score
Grade
Pivots
Resistance
$17.04
$16.69
$16.50

$16.15

Support
$15.96
$15.61
$15.42
Tweet
Growth
Description
Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA.
Peers
InterCeptRegeneron PharmaceuticalsVertex PharmaceuticalsBioMarin PharmaceuticalZoetisBristol-Myers SquibbJohnson & JohnsonMerck & Co.PfizerUltragenyx Pharmaceutical